Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 10/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15941311 | 0.94 | RAPGEF3 (1.00) | RAPGEF3 | |
| SCHEMBL15188849 | 0.94 | RAPGEF3 (1.00) | RAPGEF3 | |
| SCHEMBL15188836 | 0.86 | RAPGEF3 (0.81) | RAPGEF3 | |
| SCHEMBL15940957 | 0.86 | RAPGEF3 (0.81) | RAPGEF3 | |
| SCHEMBL15176262 | 0.83 | RAPGEF3 (0.72) | RAPGEF3 | |
| SCHEMBL15176263 | 0.83 | RAPGEF3 (0.72) | RAPGEF3 | |
| SCHEMBL15176035 | 0.82 | RAPGEF3 (0.79) | RAPGEF3 | |
| SCHEMBL15176034 | 0.82 | RAPGEF3 (0.79) | RAPGEF3 | |
| SCHEMBL15175346 | 0.81 | RAPGEF3 (1.00) | RAPGEF3 | |
| SCHEMBL15175342 | 0.81 | RAPGEF3 (1.00) | RAPGEF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2811990-B1 | MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | UNIV TEXAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9737512-B2 | Methods and compositions for treating chronic pain | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-08-22 | — | — | US | disclosed |
| US-9539256-B2 | Modulators of exchange proteins directly activated by cAMP (EPACS) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160263088-A1 | Methods and Compositions for Treating Chronic Pain | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-15 | — | — | US | disclosed |
| US-20150110809-A1 | MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150110809-A1 | MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) | RAPGEF3, RAPGEF4, CREB1 | RAPGEF3 1/4885 |
| US-20160263088-A1 | Methods and Compositions for Treating Chronic Pain | PLA2G4C, GAP43, PTGER2 | RAPGEF3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.